Valuation: Regeneron Pharmaceuticals, Inc.

Capitalization 62.91B 55.35B 51.93B 47.37B 87.26B 5,370B 98.56B 606B 237B 2,408B 236B 231B 8,951B P/E ratio 2025 *
16.6x
P/E ratio 2026 * 15.3x
Enterprise value 49.2B 43.28B 40.6B 37.04B 68.24B 4,199B 77.07B 474B 185B 1,883B 185B 181B 7,000B EV / Sales 2025 *
3.45x
EV / Sales 2026 * 2.97x
Free-Float
77.36%
Yield 2025 *
0.48%
Yield 2026 * 0.51%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.40%
1 week+2.94%
Current month-7.31%
1 month-10.73%
3 months-14.53%
6 months-39.30%
Current year-17.48%
More quotes
1 week 544.5
Extreme 544.5
603.77
1 month 525.99
Extreme 525.99
667.46
Current year 525.99
Extreme 525.99
748.29
1 year 525.99
Extreme 525.99
1,211.2
3 years 525.99
Extreme 525.99
1,211.2
5 years 441
Extreme 441
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
More quotes
Manager TitleAgeSince
President 65 31/12/2000
Chief Executive Officer 72 07/01/1988
Director of Finance/CFO 54 04/02/2024
Director TitleAgeSince
Chairman 72 08/06/2023
Director/Board Member 84 31/05/1991
Director/Board Member 84 31/05/1991
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.40%+2.94%-34.69%-16.75% 62.91B
+0.88%+0.04%+56.51%+78.36% 36.62B
-1.44%+2.63%+90.26%+51.24% 26.9B
+9.70%+12.20%+30.47%-22.33% 27.56B
+1.97%+3.44%+27.70%-46.57% 22.17B
+21.50%+27.17%+852.15%+1,520.98% 24.51B
-0.62%-0.32%+193.65%+199.62% 12.87B
+2.47%+4.40%-34.48%-48.59% 12.69B
+0.44%+7.55%+78.12%-59.29% 11.84B
+7.16%+14.49%+124.46%+617.22% 10.75B
Average +4.25%+10.77%+138.42%+227.39% 24.88B
Weighted average by Cap. +3.87%+10.59%+116.45%+187.75%
See all sector performances

Financials

2025 *2026 *
Net sales 14.25B 12.53B 11.76B 10.73B 19.76B 1,216B 22.32B 137B 53.59B 545B 53.44B 52.33B 2,027B 15.15B 13.33B 12.5B 11.4B 21.01B 1,293B 23.73B 146B 56.98B 580B 56.82B 55.64B 2,155B
Net income 3.71B 3.26B 3.06B 2.79B 5.14B 316B 5.81B 35.69B 13.94B 142B 13.91B 13.62B 527B 3.94B 3.47B 3.26B 2.97B 5.47B 337B 6.18B 37.97B 14.84B 151B 14.79B 14.49B 561B
Net Debt -13.72B -12.07B -11.32B -10.33B -19.03B -1,171B -21.49B -132B -51.6B -525B -51.46B -50.39B -1,952B -17.95B -15.79B -14.81B -13.51B -24.89B -1,532B -28.12B -173B -67.51B -687B -67.33B -65.92B -2,554B
More financial data * Estimated data
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (53.7%); - revenues from collaboration agreements (42.7%): collaboration with Sanofi (74.8% of revenues), Bayer (24.7%) and other (0.5%); - revenues from sales of technology licenses and subcontracted research services (3.6%). At the end of 2024, the group had a portfolio of approximately 40 products in clinical development.
Employees
15,106
More about the company
Date Price Change Volume
23/04/25 587.85 $ +0.40% 791,945
22/04/25 585.49 $ +4.27% 1,036,812
21/04/25 561.49 $ -0.30% 745,717
17/04/25 563.16 $ +2.53% 827,805
16/04/25 549.28 $ -1.55% 875,713

Delayed Quote Nasdaq, April 23, 2025 at 09:00 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
587.85USD
Average target price
856.75USD
Spread / Average Target
+45.74%
Consensus

Quarterly revenue - Rate of surprise